Literature DB >> 33053478

Lysins breaking down the walls of Gram-negative bacteria, no longer a no-go.

Diana Gutiérrez1, Yves Briers2.   

Abstract

Phage lysins are one of the most advanced classes of antibacterials under clinical evaluation and have a new mode of action based on peptidoglycan degradation. Lysins were initially excluded from use against Gram-negative pathogens because of their impermeable outer membrane, but are now increasingly developed as effective antibacterials against these critical priority pathogens. Generally, three routes of investigation have been recently explored and advanced to different extents, including the use of lysins that possess intrinsic activity due to a positively charged C-terminus that destabilizes the outer membrane, the use of physical or chemical means to disrupt the outer membrane integrity and protein engineering to equip the lysin with the necessary tools to overcome the outer membrane.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Year:  2020        PMID: 33053478     DOI: 10.1016/j.copbio.2020.08.014

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  12 in total

Review 1.  Polymeric Coatings and Antimicrobial Peptides as Efficient Systems for Treating Implantable Medical Devices Associated-Infections.

Authors:  Irina Negut; Bogdan Bita; Andreea Groza
Journal:  Polymers (Basel)       Date:  2022-04-15       Impact factor: 4.967

2.  Engineering a Lysin with Intrinsic Antibacterial Activity (LysMK34) by Cecropin A Fusion Enhances Its Antibacterial Properties against Acinetobacter baumannii.

Authors:  Karim Abdelkader; Diana Gutiérrez; Héctor Tamés-Caunedo; Patricia Ruas-Madiedo; Amal Safaan; Ahmed S Khairalla; Yasser Gaber; Tarek Dishisha; Yves Briers
Journal:  Appl Environ Microbiol       Date:  2021-10-20       Impact factor: 5.005

Review 3.  Essential Topics for the Regulatory Consideration of Phages as Clinically Valuable Therapeutic Agents: A Perspective from Spain.

Authors:  Roberto Vázquez; Roberto Díez-Martínez; Pilar Domingo-Calap; Pedro García; Diana Gutiérrez; Maite Muniesa; María Ruiz-Ruigómez; Rafael Sanjuán; María Tomás; María Ángeles Tormo-Mas; Pilar García
Journal:  Microorganisms       Date:  2022-03-26

4.  Engineered endolysin-based "artilysins" for controlling the gram-negative pathogen Helicobacter pylori.

Authors:  Dengyuan Xu; Shanshan Zhao; Jun Dou; Xiaofeng Xu; Yanyan Zhi; Liangzhu Wen
Journal:  AMB Express       Date:  2021-04-28       Impact factor: 3.298

5.  Bacteriophage Lytic Enzyme P9ly as an Alternative Antibacterial Agent Against Antibiotic-Resistant Shigella dysenteriae and Staphylococcus aureus.

Authors:  Feng Wang; Yao Xiao; Yao Lu; Zheng-Yu Deng; Xian-Yu Deng; Lian-Bing Lin
Journal:  Front Microbiol       Date:  2022-02-14       Impact factor: 5.640

6.  Editorial: Bacteriophages and Their Lytic Enzymes as Alternative Antibacterial Therapies in the Age of Antibiotic Resistance.

Authors:  Carlos São-José; Ana Rita Costa; Luís D R Melo
Journal:  Front Microbiol       Date:  2022-03-25       Impact factor: 5.640

Review 7.  An Overview of Antimicrobial Activity of Lysozyme and Its Functionality in Cheese.

Authors:  Nasim Khorshidian; Elham Khanniri; Mohammad Reza Koushki; Sara Sohrabvandi; Mojtaba Yousefi
Journal:  Front Nutr       Date:  2022-03-09

8.  Phage vB_PaeS-PAJD-1 Rescues Murine Mastitis Infected With Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Zhaofei Wang; Yibing Xue; Ya Gao; Mengting Guo; Yuanping Liu; Xinwei Zou; Yuqiang Cheng; Jingjiao Ma; Hengan Wang; Jianhe Sun; Yaxian Yan
Journal:  Front Cell Infect Microbiol       Date:  2021-06-11       Impact factor: 5.293

Review 9.  Application of Bacteriophages to Limit Campylobacter in Poultry Production.

Authors:  Elena G Olson; Andrew C Micciche; Michael J Rothrock; Yichao Yang; Steven C Ricke
Journal:  Front Microbiol       Date:  2022-01-05       Impact factor: 5.640

Review 10.  Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application.

Authors:  Katarzyna M Danis-Wlodarczyk; Daniel J Wozniak; Stephen T Abedon
Journal:  Antibiotics (Basel)       Date:  2021-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.